Biomedtracker analysts tracked 99 events at ESMO 2026, from antibody-drug conjugates to the first positive Phase III trial of an individualized mRNA cancer therapy. Some readouts missed their endpoints, including KEYNOTE-866 in MIBC and SigVie-002 in NSCLC.
Each write-up gives our likelihood of approval and any change to it, and nearly all add an analyst takeaway and commentary on clinical and commercial impact. You can see at a glance how a result moves the odds for a drug and what it could mean for the competitive landscape.
This sample draws six events from the full 392-page report across 22 pages. Tovecimig in biliary tract cancer is shown in full, and the other five are excerpts.
